Literature DB >> 32533873

Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata.

Taisuke Ito1, Reiko Kageyama1, Shinsuke Nakazawa1, Tetsuya Honda1.   

Abstract

Alopecia areata has basically been understood as a type 1 inflammatory disease. Activated NKG2D+ CD8+ cells produce the Th1 cytokine interferon-γ, which leads to the disruption of immune tolerance of hair follicles and the exposure of self-antigens. This results in dense inflammatory cell infiltration and apoptosis around hair follicles, inducing hair loss. A well-known complication of alopecia areata is atopic dermatitis, a typical type 2 inflammatory disease. Hair scientists have shied away from confronting and understanding how alopecia areata, a type 1 inflammatory disease, and atopic dermatitis, a type 2 inflammatory disease, can occur together. This review summarizes the research on the cytokine balance in alopecia areata and then focuses on the classification of the cytokine balance in alopecia areata, including the classification of atopic dermatitis into extrinsic and intrinsic types. Dupilumab reportedly showed dual efficacy in a patient with concomitant atopic dermatitis and alopecia areata, supporting our own experience. Elevated Th2 cytokine levels have also been reported in patients with alopecia areata, with increased serum IL-4, IL-5, IL-6 levels, high IgE levels and elevated eosinophil levels. Because local immunotherapy is a treatment that induces Th2-type inflammation, it may worsen the condition of alopecia areata patients with extrinsic atopic dermatitis. It is desirable to select appropriate treatments with consideration of the cytokine balance.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Th1; Th2; alopecia areata; atopic dermatitis; dupilumab

Year:  2020        PMID: 32533873     DOI: 10.1111/exd.14129

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  6 in total

Review 1.  Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.

Authors:  Cheng Zhou; Xiangqian Li; Chen Wang; Jianzhong Zhang
Journal:  Clin Rev Allergy Immunol       Date:  2021-08-17       Impact factor: 8.667

2.  Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.

Authors:  Zhenpeng Dai; James Chen; Yuqian Chang; Angela M Christiano
Journal:  JCI Insight       Date:  2021-04-08

3.  Remission of Alopecia Universalis after 1 Year of Treatment with Dupilumab in a Patient with Severe Atopic Dermatitis.

Authors:  Maurizio Romagnuolo; Mauro Barbareschi; Simona Tavecchio; Luisa Angileri; Silvia Mariel Ferrucci
Journal:  Skin Appendage Disord       Date:  2021-07-27

4.  Rapid Enlargement of Vitiligo Vulgaris after Initiation of Dupilumab for Atopic Dermatitis: A Case Report.

Authors:  Shintaro Takeoka; Masahiro Kamata; Ikumi Yokoi; Aya Takehara; Yayoi Tada
Journal:  Acta Derm Venereol       Date:  2021-10-28       Impact factor: 3.875

5.  Alopecia Areata and Dexamethasone Mini-Pulse Therapy, A Prospective Cohort: Real World Evidence and Factors Related to Successful Response.

Authors:  Manuel Sánchez-Díaz; Trinidad Montero-Vilchez; Ahinoa Bueno-Rodriguez; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  J Clin Med       Date:  2022-03-18       Impact factor: 4.241

6.  Ayurveda-based Botanicals as Therapeutic Adjuvants in Paclitaxel-induced Myelosuppression.

Authors:  Akash Saggam; Prathamesh Kale; Sushant Shengule; Dada Patil; Manish Gautam; Girish Tillu; Kalpana Joshi; Sunil Gairola; Bhushan Patwardhan
Journal:  Front Pharmacol       Date:  2022-02-22       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.